Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

25.0%

4 terminated/withdrawn out of 16 trials

Success Rate

60.0%

-26.5% vs industry average

Late-Stage Pipeline

19%

3 trials in Phase 3/4

Results Transparency

17%

1 of 6 completed trials have results

Key Signals

5 recruiting1 with results

Enrollment Performance

Analytics

Phase 2

8(50.0%)

Phase 1

4(25.0%)

Phase 3

3(18.8%)

N/A

1(6.3%)

16Total

Phase 2(8)

Phase 1(4)

Phase 3(3)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (16)

Showing 16 of 16 trials

NCT04031677Phase 3Recruiting

Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma

Role: collaborator

NCT03585465Phase 1Active Not Recruiting

Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors

Role: collaborator

NCT02115074Phase 1Completed

Safety of Fluvastatin-Celebrex Association in Low-grade and High Grade Optico-chiasmatic Gliomas

Role: collaborator

NCT04111978Phase 3Recruiting

MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)

Role: collaborator

NCT05360264Phase 2Terminated

tailOred dRug repurposIng of dEcitabine in KRAS-dependeNt refracTory pAncreaTic cancEr

Role: collaborator

NCT05393791Phase 2Recruiting

Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC

Role: collaborator

NCT04498767Not ApplicableRecruiting

Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)

Role: collaborator

NCT02942758Phase 2Terminated

Low-dose AZA, Pioglitazone, ATRA Versus Standard-dose AZA in Patients >=60 Years With Refractory AML

Role: collaborator

NCT05080556Phase 2Recruiting

Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer

Role: collaborator

NCT03306472Phase 2Completed

A Pre-operative Window Study of Letrozole Plus PR Agonist (Megestrol Acetate) Versus Letrozole Alone in Post-menopausal Patients With ER-positive Breast Cancer

Role: collaborator

NCT04518124Phase 2Completed

Propranolol in Angiosarcoma

Role: collaborator

NCT02304289Phase 1Terminated

Dose-Escalation Study Evaluating the Safety and Pharmacokinetics of Artesunate in Patients With Hepatocellular Carcinoma

Role: collaborator

NCT02770378Phase 1Completed

A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma

Role: collaborator

NCT03192059Phase 2Completed

Study of Pembrolizumab, Radiation and Immune Modulatory Cocktail in Cervical/Uterine Cancer

Role: collaborator

NCT01806259Phase 3Completed

Ketorolac in Breast Cancer Surgery

Role: collaborator

NCT01210378Phase 2Terminated

Nitroglycerin in Non-small Cell Lung Cancer

Role: collaborator

All 16 trials loaded